Torthaí cuardaigh - Julio D. Duarte

  • 1 - 13 toradh as 13 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Pharmacogenetics to guide cardiovascular drug therapy

    Pharmacogenetics to guide cardiovascular drug therapy de réir Julio D. Duarte, Larisa H. Cavallari

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics

    Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics de réir Julio D. Duarte, Rhonda M. Cooper‐DeHoff

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Implementation of inpatient models of pharmacogenetics programs

    Implementation of inpatient models of pharmacogenetics programs de réir Larisa H. Cavallari, Craig R. Lee, Julio D. Duarte, Edith A. Nutescu, Kristin Weitzel, George A. Stouffer, Julie A. Johnson

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics

    Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics de réir Caitrin W. McDonough, Sarah E. Burbage, Julio D. Duarte, Yan Gong, Taimour Langaee, Stephen T. Turner, John G. Gums, Arlene B. Chapman, Kent R. Bailey, Amber L. Beitelshees, Eric Boerwinkle, Carl J. Pepine, Rhonda M. Cooper‐DeHoff, Julie A. Johnson

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Genetic polymorphisms in SLC5A2 are associated with clinical outcomes and dapagliflozin response in heart failure patients

    Genetic polymorphisms in SLC5A2 are associated with clinical outcomes and dapagliflozin response in heart failure patients de réir Ahmed E. Abou Warda, Rylie M. Flohr, Rania M. Sarhan, Mohamed Nabil Salem, Heba F. Salem, Ayman Moharram, Abdullah Salah Alanazi, Christelle Lteif, Brian E. Gawronski, Leanne Dumeny, Tariq G. Alsahli, Khaled Elenizi, Bassem Zarif, Neven Sarhan, Julio D. Duarte

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Feasibility of Implementing a Comprehensive Warfarin Pharmacogenetics Service

    Feasibility of Implementing a Comprehensive Warfarin Pharmacogenetics Service de réir Edith A. Nutescu, Katarzyna Drozda, Adam P. Bress, William Galanter, James M. Stevenson, Thomas D. Stamos, Ankit A. Desai, Julio D. Duarte, Victor R. Gordeuk, David Peace, Shrihari S. Kadkol, Carol L. Dodge, Santosh L. Saraf, John Garofalo, Jerry A. Krishnan, Joe G. N. Garcia, Larisa H. Cavallari

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data

    Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data de réir Nita A. Limdi, Larisa H. Cavallari, Craig R. Lee, William B. Hillegass, Ann Holmes, Todd C. Skaar, Maria Pisu, Chrisly Dillon, Amber L. Beitelshees, Philip E. Empey, Julio D. Duarte, Vakaramoko Diaby, Yan Gong, Julie A. Johnson, John A. Graves, Shawn Garbett, Zilu Zhou, Josh F. Peterson

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for <i>CYP2D6</i>, <i>ADRB1</i>, <i>ADRB2</i>, <i>ADRA2C</i>, <i>GRK4</i>, and <i>GRK5</i> Genotypes and Beta‐Blocker Therapy

    Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for <i>CYP2D6</i>, <i>ADRB1</i>, <i>ADRB2</i>, <i>ADRA2C</i>, <i>GRK4</i>, and <i>GRK5</i> Genotypes and Beta‐B... de réir Julio D. Duarte, Cameron D. Thomas, Craig R. Lee, Rachel Huddart, José A. G. Agúndez, Jordan Baye, Andrea Gaedigk, Teri E. Klein, David E. Lanfear, Andrew A. Monte, Mohamed Nagy, Matthias Schwab, C. Michael Stein, Chakradhara Rao S. Uppugunduri, Ron H. N. van Schaik, Roseann S. Donnelly, Kelly E. Caudle, Jasmine A. Luzum

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing

    Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing de réir Julio D. Duarte, Rachel Dalton, Amanda L. Elchynski, D. Max Smith, Emily J. Cicali, James C. Lee, Benjamin Q. Duong, Natasha Petry, Christina L. Aquilante, Amber L. Beitelshees, Philip E. Empey, Julie A. Johnson, Aniwaa Owusu Obeng, Amy L. Pasternak, Victoria M. Pratt, Laura B. Ramsey, Sony Tuteja, Sara L. Van Driest, Kristin Wiisanen, J. Kevin Hicks, Larisa H. Cavallari

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Impact of the <i>CYP2C19*17</i> Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

    Impact of the <i>CYP2C19*17</i> Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention de réir Craig R. Lee, Cameron D. Thomas, Amber L. Beitelshees, Sony Tuteja, Philip E. Empey, James C. Lee, Nita A. Limdi, Julio D. Duarte, Todd C. Skaar, Yiqing Chen, Kelsey J. Cook, James C. Coons, Chrisly Dillon, Francesco Franchi, Jay Giri, Yan Gong, Rolf P. Kreutz, Caitrin W. McDonough, James M. Stevenson, Karen E. Weck, Dominick J. Angiolillo, Julie A. Johnson, George A. Stouffer, Larisa H. Cavallari

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    <i>CYP2C19</i> Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings

    <i>CYP2C19</i> Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings de réir Amber L. Beitelshees, Cameron D. Thomas, Philip E. Empey, George A. Stouffer, Dominick J. Angiolillo, Francesco Franchi, Sony Tuteja, Nita A. Limdi, James C. Lee, Julio D. Duarte, Rolf P. Kreutz, Todd C. Skaar, James C. Coons, Jay Giri, Caitrin W. McDonough, Rachel Rowland, James M. Stevenson, Thuy Nhu Thai, Mark R. Vesely, Jacob T. Wellen, Julie A. Johnson, Almut G. Winterstein, Larisa H. Cavallari, Craig R. Lee

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Multisite Investigation of Strategies for the Implementation of <i>CYP2C19</i> Genotype‐Guided Antiplatelet Therapy

    Multisite Investigation of Strategies for the Implementation of <i>CYP2C19</i> Genotype‐Guided Antiplatelet Therapy de réir Philip E. Empey, James M. Stevenson, Sony Tuteja, Kristin Weitzel, Dominick J. Angiolillo, Amber L. Beitelshees, James C. Coons, Julio D. Duarte, Francesco Franchi, Linda Jo Bone Jeng, Julie A. Johnson, Rolf P. Kreutz, Nita A. Limdi, Kristin A. Maloney, Aniwaa Owusu Obeng, Josh F. Peterson, Natasha Petry, Victoria M. Pratt, Fabiana Rollini, Stuart A. Scott, Todd C. Skaar, Mark R. Vesely, George A. Stouffer, Russell A. Wilke, Larisa H. Cavallari, Craig R. Lee

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

    Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention de réir Larisa H. Cavallari, Craig R. Lee, Amber L. Beitelshees, Rhonda M. Cooper‐DeHoff, Julio D. Duarte, Deepak Voora, Stephen E. Kimmel, Caitrin W. McDonough, Yan Gong, Chintan V. Dave, Victoria M. Pratt, Tameka D. Alestock, R. David Anderson, Jorge Alsip, Amer Ardati, Brigitta C. Brott, Lawrence M. Brown, Supatat Chumnumwat, Michael Clare‐Salzler, James C. Coons, Joshua C. Denny, Chrisly Dillon, Amanda R. Elsey, Issam S. Hamadeh, Shuko Harada, William B. Hillegass, Lindsay J. Hines, Richard B. Horenstein, Lucius A. Howell, Linda Jo Bone Jeng, Mark D. Kelemen, Yee Ming Lee, Oyunbileg Magvanjav, May E. Montasser, David R. Nelson, Edith A. Nutescu, Devon Nwaba, Ruth E. Pakyz, Kathleen Palmer, Josh F. Peterson, Toni I. Pollin, Alison H. Quinn, Shawn Robinson, Jamie Schub, Todd C. Skaar, D. Max Smith, Vindhya Sriramoju, Petr Starostik, Tomasz Styŝ, James M. Stevenson, Nicholas Varunok, Mark R. Vesely, Dyson T. Wake, Karen E. Weck, Kristin Weitzel, Russell A. Wilke, James H. Willig, Yuqi Zhao, Rolf P. Kreutz, George A. Stouffer, Philip E. Empey, Nita A. Limdi, Alan R. Shuldiner, Almut G. Winterstein, Julie A. Johnson

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: